- Stocks
- Pharma & Healthcare
- Bacil Pharma
Bacil Pharma share price
NSE: BACPHARPharma & HealthcareDrug Manufacturers - Specialty & Generic
Bacil Pharma at a glance
With a market capitalisation of ₹58 Cr, it ranks 2985th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 1.6% in FY25. Promoters held 0.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹58 CrRank 2985 on NSE
- Price to book
- 2.33×FY25
- ROE
- 1.6%FY25
- ROCE
- 1.6%FY25
- Debt to equity
- 0.01FY25
- Net profit margin
- 0.0%FY25
- Book value / share
- ₹18.20FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Bacil Pharma financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | −₹0 Cr | −₹0 Cr | −₹4 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr |
| Net profit | −₹0 Cr | −₹0 Cr | −₹4 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr |
| EPS (₹) | −₹0.54 | −₹0.41 | −₹6.55 | −₹0.17 | −₹0.10 | ₹0.64 |
| Cash from operations | −₹0 Cr | −₹0 Cr | −₹4 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹25 Cr |
Bacil Pharma shareholding pattern
| Holder | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 0.08% | 0.08% | 0.00% | 0.00% |
| Non-institutions | 99.92% | 99.92% | 100.00% | 100.00% |
Bacil Pharma vs peers
The listed Pharma & Healthcare companies nearest to Bacil Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SAMRATPHSamrat Pharma | — | — | — | ₹61 Cr | — | — |
| ROYALRoyal Sense | — | — | — | ₹59 Cr | — | — |
| BACPHARBacil Pharma | — | — | — | ₹58 Cr | — | — |
| VEERHEALTHVeerhealth Care | — | — | — | ₹58 Cr | — | — |
| CONSTRONICConstronics Inf | — | — | — | ₹57 Cr | — | — |
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
Ask anything about Bacil Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against BACPHAR's own history. Try: “Why has BACPHAR moved over the last three months?” · “Backtest a 50-day moving-average crossover on BACPHAR over five years” · “Compare BACPHAR with SAMRATPH on margins and valuation”
Frequently asked questions about Bacil Pharma
What is the market cap of Bacil Pharma?
Bacil Pharma's market capitalisation is ₹58 Cr (₹58 Cr) at the 22 Oct 2026 close, ranking 2985th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Bacil Pharma?
Return on equity was 1.6% in FY25 and return on capital employed was 1.6% in FY25 (standalone figures).
Is Bacil Pharma a debt-free company?
Bacil Pharma is close to debt-free: its debt-to-equity ratio was 0.01 in FY25.
What is the shareholding pattern of Bacil Pharma?
As of 30 Jun 2026: promoters 0.00%, non-institutions 100.00%.
Who are Bacil Pharma's competitors?
The listed Pharma & Healthcare companies closest to Bacil Pharma by market cap are Samrat Pharma, Royal Sense, Veerhealth Care, Constronics Inf, Kabra Drugs and Bandaram Pharma.
Is Bacil Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Bacil Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BACPHAR against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text